Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
“The accumulation of triglycerides in the liver of obese humans is associated with the promotion of lipogenesis in hepatocytes (Donnelly et al., 2005).”
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781
“60% of fatty acids to newly synthesized triglyceride in the liver while DNL contributes 26%.(64) Rectal infusion of acetate and propionate has demonstrated a 40% reduction in serum FFA.”
BackgroundMechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
“Free fatty acid delivery to the liver accounts for almost two-thirds of its lipid accumulation.(12) Abbreviations: AhR, aryl hydrocarbon receptor; ATF-6, activating transcription factor 6; ChREBP, carbohydrate response element-binding protein; DGAT, diacylglycerol acyltransferase; DNL, de novo lipogenesis; ER, endopla…”
BackgroundNonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
“Insulin resistance is a determinant for the development of type 2 diabetes, and it also contributes to the pathogenesis of NAFLD.”
InfluentialCornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
“Fat deposition in the liver has been shown to be primarily due to an increased influx of fatty acids to the liver, most likely as a result of the increased lipolysis associated with obesity and insulin resistance and as a result of increased hepatic de novo lipogenesis (425).”
BackgroundObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, chylomicron remnants, low-density lipoprotein [LDL]), which occur with increased plasma concentrations of ApoC3, as well as from circulating fatty acids, a major source for hepatic triglyceride synthesis (Donnelly et al., 2005).”
BackgroundJung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“It has been estimated that nearly 60% of ectopic hepatic triglycerides in obese NAFLD patients derive from FFA released from adipose tissue (295).”
BackgroundMolecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
“The importance of DNL in NAFLD is further supported by studies, showing that in obese patients with NAFLD, approximately 26% of hepatic triglycerides were derived from DNL and that these patients were unable to regulate DNL when transitioning from fasting to fed state [40].”
BackgroundHodson, L., Skeaff, C. M., & Fielding, B. A. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.03.003 · Cited by 1,309
“Other factors that may up regulate DNL include meal consumption [214], non-alcoholic fatty liver disease and hypertriglyceridaemia [217,218].”
BackgroundRole of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease
Chen, Z., Tian, R., She, Z., Cai, J., & Li, H. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.025 · Cited by 1,279
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Triglyceride Metabolism in the Liver
Alves‐Bezerra, M., & Cohen, D. E. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170012 · Cited by 1,016
“However, in addition to the enhanced FA uptake, increased DNL can contribute substantially to hepatic steatosis (72).”
InfluentialNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
The Human Gut Microbiome – A Potential Controller of Wellness and Disease
Kho, Z. Y., & Lal, S. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01835 · Cited by 1,104
“It is associated with elevated energy intake and decreased energy expenditure, causing excessive fat accumulation with raised body mass index (BMI ≥ 30kg/m2), and is linked to metabolic syndrome, posing obese individuals to have a higher risk of developing obesityassociated disorders (for example cardiovascular diseas…”
BackgroundThe role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014) · Nature · doi:10.1038/nature13478 · Cited by 1,136
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
“Adipose tissue lipolysis is the major source of fatty acids delivered to the liver, whereas DNL normally contributes only about 5%; in patients with NASH, DNL may contribute up to 26% of the fatty acids.(40) Relatively minor contributors to the hepatic free fatty acid pool include uptake of short chain fatty acids del…”
BackgroundLambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069
“Using an established multiple stableisotope procedure,(12,14,16,19) the potential FA sources that contribute to production of lipoprotein-TG palmitate (dietary fat, adipose FA, and hepatic lipogenesis) were each labeled with a different palmitate isotope and expressed as both absolute concentration and a proportion to…”
Self-citationThe interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
“1B. Key Points 2 • Insulin activates DNL via PI3K-mediated FAS expression • SREBP-1c and ChREBP transcriptionally activate FAS and ACC as well as VLDL assembly • Insulin represses peripheral lipolysis and liberation of FFAs from adipocytes • Insulin represses autophagy via activation of mTOR and repression of FoxO pho…”
BackgroundInfluentialThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
Kawano, Y., & Cohen, D. E. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0758-5 · Cited by 969
“De novo lipogenesis plays a substantial role in the pathogenesis of NAFLD, accounting for 26 % hepatic triglycerides in human subjects [7].”
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
“Our data suggest that the increase in VLDL-TG secretion rate in obese subjects who have NAFLD is primarily caused by the availability of nonsystemic fatty acids derived from lipolysis of IHTG, not VAT, because VAT volume was the same in both groups and de novo lipogenesis accounts for up to 20% of the fatty acids secr…”
BackgroundInfluentialCusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
“(Duckworth et al., 1998).”
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 856
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
“DNL is increased in NAFLD patients compared to healthy subjects (72) and fails to increase in the postprandial period (73).”
BackgroundPalmitic Acid: Physiological Role, Metabolism and Nutritional Implications
Carta, G., Murru, E., Banni, S., & Manca, C. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00902 · Cited by 809
“resistance and a dysregulated fat deposition and distribution (Donnelly et al., 2005).”
BackgroundInfluentialLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
“Increased delivery of free fatty acids (FFA) from insulinresistant adipose tissue, intrahepatic de novo lipogenesis, and dietary fat are the major mechanisms underlying triglyceride accumulation [12].”
BackgroundLipolysis: cellular mechanisms for lipid mobilization from fat stores
Grabner, G. F., Xie, H., Schweiger, M., & Zechner, R. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00493-6 · Cited by 765
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialThe role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771
“but stable isotope studies have demonstrated that up to only 15% of intrahepatic lipid is derived from dietary fat”
BackgroundLiver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
“used a multiple-stable-isotope method, demonstrating that approximately 60% of liver triglyceride content derived from FFA influx from adipose tissue, 26% from DNL, and 15% from diet.(31) This contrasts with healthy individuals in whom DNL contributes <5% of hepatic triglyceride formation.”
MethodLiver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 755
Wei, Y., Wang, D., Topczewski, F., & Pagliassotti, M. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00644.2005 · Cited by 735
“The sources of fatty acids stored in liver and secreted via lipoproteins in patients with NAFLD has recently been estimated (8).”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c
Ferré, P., & Foufelle, F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01275.x · Cited by 704
“showed in patients with NAFLD that 59% of the TG labelled in the liver arose from circulating fatty acid flux (mainly from adipose tissue lipolysis), 26% from de novo lipogenesis and 15% from the diet [9].”
BackgroundKammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
“A more recent analysis of obese patients with NAFLD found that while 60 % of liver triglycerides are derived from plasma free fatty acid, which themselves are derived from adipose tissue lipolysis, 26 % of liver fat in these individual came from DNL and another 15 % from dietary fat [44].”
BackgroundMetabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“In white adipocytes, fatty acids are liberated by lipolysis during catabolic states and these FFA are the principal source for VLDL synthesis in the liver [95].”
BackgroundLipid droplets and liver disease: from basic biology to clinical implications
Gluchowski, N. L., Becuwe, M., Walther, T. C., & Farese, R. V. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.32 · Cited by 677
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
“Indeed, increased delivery of NEFA to the liver in humans is associated with fatty liver [29, 30] and has been linked to hepatic insulin resistance [31–33].”
BackgroundRicchi, M., Odoardi, M. R., Carulli, L., Anzivino, C., Ballestri, S., Pinetti, A., Fantoni, L. I., Marra, F., Bertolotti, M., Banni, S., et al. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05733.x · Cited by 645
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
“The contributions of dietary lipid intake, lipogenesis, lipolysis, and lipoprotein secretion to the development of NAFLD have all been studied in humans (Choi and Ginsberg, 2011; Diraison et al., 2003; Donnelly et al., 2005; Fabbrini et al., 2008).”
BackgroundSelf-citationMolecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
De novo lipogenesis in health and disease
Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., & Zaidi, N. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.003 · Cited by 611
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Masarone, M., Rosato, V., Dallio, M., Gravina, A. G., Aglitti, A., Loguercio, C., Federico, A., & Persico, M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9547613 · Cited by 648
“Besides the hypothesis of a primary mitochondrial dysfunction, it is noted that, during the early phase of fatty infiltration in the hepatocytes, several adaptive metabolic mechanisms are mediated by mitochondrial activity, with the aim of partitioning the lipotoxic FFAs into stable intracellular triglyceride stores,…”
BackgroundAn Emerging Role of mTOR in Lipid Biosynthesis
Laplante, M., & Sabatini, D. M. (2009) · Current Biology · doi:10.1016/j.cub.2009.09.058 · Cited by 620
“A recent study performed in obese humans revealed an important role of de novo lipogenesis in the excessive accumulation of hepatic triglycerides [19].”
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“This could be secondary to inhibition of mitochondrial β-oxidation due to inhibition of CPT-1 by an accumulation of malonyl-CoA (133, 159).”
BackgroundThe role of lipid droplets in metabolic disease in rodents and humans
Greenberg, A. S., Coleman, R. A., Kraemer, F. B., McManaman, J. L., Obin, M. S., Puri, V., Yan, Q.-W., Miyoshi, H., & Mashek, D. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46069 · Cited by 621
A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism
Herman, M. A., Peroni, O. D., Villoria, J., Schön, M. R., Abumrad, N. A., Blüher, M., Klein, S., & Kahn, B. B. (2012) · Nature · doi:10.1038/nature10986 · Cited by 596
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631
Modeling type 2 diabetes in rats using high fat diet and streptozotocin
Skovsø, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12235 · Cited by 596
Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
Milić, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9330 · Cited by 583
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
“During postprandial periods, chylomicron incorporation of dietary fats or de novo lipogenesis of dietary glucose mediate this flux 176 .”
The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J. L., Hugol, D., Coussieu, C., Basdevant, A., Hen, A. B., Bedossa, P., et al. (2006) · Diabetes · doi:10.2337/db06-0133 · Cited by 607
“Recent stable isotope studies in obese NAFLD patients demonstrated that nearly 60% of the triacylglycerol found in the liver arose from the nonesterified fatty acid pool in the serum, 60–80% of which comes from adipose tissue lipolysis (31).”
BackgroundDe novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
“(3) ACC As discussed above ACC catalyses the synthesis of malonyl-CoA in DNL, providing the monomer from which FAs are synthesised.”
BackgroundMethodInfluentialDysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“Importantly, the molar ratio of VLDL-TG (particle TG content) to VLDL-ApoB100 (the number of particles) is elevated in nondiabetic obese individuals with high intrahepatic TG (measured by MRS), suggesting that the secreted VLDL particles are larger and resemble the pro-atherogenic VLDL1 [65].”
BackgroundInfluentialCellular and Molecular Mechanisms of Liver Injury
Malhi, H., & Gores, G. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.002 · Cited by 560
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
Arroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527
“This is due to an increased FFA uptake from dietary sources, increased de novo lipogenesis [59], and enhanced lipolysis in adipose tissue, which increases FFA delivery to the liver [60,61].”
BackgroundFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
“ChREBP knockdown’s selective effect on circulating triglycerides but not steatosis in the experiment described above highlights the fact that fat accretion in lipid droplets and VLDL secretion are distinct processes.”
BackgroundInfluentialThe Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
“Published data indicate that increased DNL rates contribute to excess hepatic TAG synthesis and deposition, causing NAFLD [20].”
BackgroundMethodNon-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Non alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed Central · Cited by 718
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
“Patients with NAFLD display elevated de novo lipogenesis, which reflects the inability for insulin to impede lipogenesis (Donnelly et al., 2005).”
BackgroundMolecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
Malhi, H., & Gores, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091980 · Cited by 538
“In this study, adipose tissue derived circulating FFAs contributed to 82% and 62% of the total circulating pool in the fasted and fed states, respectively, which, in turn, provided 59% and 62% of FFAs in liver and circulating triacylglycerol-rich lipoprotein particles, respectively.(15) Thus, the bulk of hepatic triac…”
BackgroundPathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 539
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
“[53] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ.”
BackgroundWang, D., Wei, Y., & Pagliassotti, M. J. (2006) · Endocrinology · doi:10.1210/en.2005-0570 · Cited by 529
“Steatosis is the earliest and most prevalent stage of NAFLD, often referred to as the “first hit.””
BackgroundInfluentialNon-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.